与「ARTO」相关的搜索结果

ARTO long-term analysis Adding SBRT to abiraterone acetate + prednisone + ADT may improve outcomes in selected patients with oligometastatic CRPC. At 53-month median follow-up • OS: not reached vs 50 mo • HR 0.55; p=0.021 • bPFS: 44 vs 18 mo • rPFS: 44 vs 17 mo • 4-yr PC-specific survival: 86.6% vs 67.7% No new safety concerns were reported. @MicheleAquilano @alessiobruni @BarbaraJereczek @GabSimontacchi @PierluigiBonomo @ChadTangMD #ProstateCancer# #GUOncology# #SBRT# #Oncology#

Excited to share the results of the #ARTO# trial. After a median f-up of 53 months, Adding SBRT to abiraterone + ADT significantly improved overall survival (HR 0.55). @dicataldovanes1 @BarbaraJereczek @Ric_Campi @ChadTangMD @TheLancetOncol @ESTRO_RT